Based on a retrospective study shared on October 20 at the American College of Chest Physicians (CHEST) 2026 Annual Meeting in Phoenix, asthma sufferers given proton pump inhibitors without an ulcer-related diagnosis experienced a 60% higher frequency of yearly exacerbations.
Adults taking the acid-suppressing drugs experienced significantly worse clinical outcomes over a one-year period than non-users, researchers announced on October 20 at the American College of Chest Physicians Annual Meeting in Phoenix. The retrospective investigation tracked patients treated with biologic therapies between 2014 and 2025, utilizing data from the TriNetX US Collaborative Network.
Investigators isolated empirical proton pump inhibitor use by excluding individuals with documented gastroesophageal reflux disease, Barrett esophagus, peptic ulcer disease, eosinophilic esophagitis, or esophageal varices. Propensity-score matching across 105 clinical and demographic variables yielded two balanced cohorts of 1,228 patients each.
“Clinicians should carefully reassess the necessity of chronic PPI therapy in biologic-treated asthma patients without clear ulcer-related indications,” Navneet Gupta, MBBS, an internal medicine physician at Allegheny Health Network in Pittsburgh, told attendees.
| Clinical Outcome | Proton Pump Inhibitor Users | Non-Users |
|---|---|---|
| Asthma Exacerbations | 31.9% | 22.6% |
| Rescue Corticosteroid Use | 72% | 40% |
| Respiratory Infections | 8.4% | 2.3% |
| Emergency Room Visits | 15.6% | 8.4% |
| ICU Admissions | 4.3% | 1.2% |
Before matching, patients taking the medications averaged 10 years older and showed higher baseline rates of hypertension and diabetes. Following the adjustments, the data revealed stark differences in acute healthcare utilization and infection rates between the two groups.
Rescue systemic corticosteroid use climbed to 72% among drug users compared with 40% for non-users. Respiratory infections likewise affected 8.4% of patients taking the suppressors versus 2.3% of unexposed individuals.
Emergency department visits reached 15.6% for the treatment group against 8.4% for controls. Intensive care unit admissions occurred in 4.3% of drug users compared to 1.2% of non-users, though all-cause mortality showed no significant variance between cohorts.
Prior trials evaluated potential harms of acid suppression in general obstructive airway disease, but this project focused explicitly on difficult-to-treat asthma populations receiving biologic treatments such as omalizumab, mepolizumab, benralizumab, reslizumab, dupilumab, or tezepelumab.
According to Mario Castro, MD, MPH, a professor of medicine and chief of the Division of Pulmonary, Critical Care and Sleep Medicine at the University of Kansas Medical Center in Kansas City, the results highlight improper prescribing practices.
“I think it was important for a real-world study to be done with PPI because a lot of these trials that had been done over 10 years ago, and yet still I see clinicians using PPI inappropriately in uncontrolled asthma,” Castro said.
Authors recommended proactive medication reviews, explicit chart documentation for drug indications, and systematic deprescribing protocols to curtail unnecessary exposure. “Proactive medication reconciliation, clear documentation of indication, and structured deprescribing strategies may reduce unnecessary long-term exposure and help mitigate preventable morbidity in this vulnerable population,” said Joshua Le, MD.
Worth a look